Add BrightSurf on Google Email

One injection stops diabetes in its tracks

A single injection of FGF1 protein restores blood sugar levels to a healthy range for over two days, reversing insulin insensitivity and the underlying cause of diabetes. This breakthrough discovery offers a new method to control glucose with a safer and more effective treatment.

SourceSalk Institute·JournalNature·DateJul 16, 2014

The Lancet: Largest study to date finds insulin pumps result in better blood sugar control than multiple daily injections in people with type 2 diabetes

The OpT2mise trial found that insulin pumps result in better blood sugar control than multiple daily injections in people with type 2 diabetes. The study showed that patients using the pumps achieved a significantly greater reduction in average blood sugar levels and spent less time in hyperglycaemia.

SourceThe Lancet·JournalThe Lancet·DateJul 2, 2014

New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo

A post-hoc analysis of patients with type 2 diabetes found that intensification of insulin therapy with Januvia (sitagliptin) 100 mg once-daily resulted in lower incidence of nighttime hypoglycemia compared to placebo. This is a positive finding for treatment approaches aimed at lowering nocturnal hypoglycemia.

Late-breaking observational data show patients with type 2 diabetes taking JANUVIA (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin

A retrospective cohort study found patients taking JANUVIA and metformin initiated insulin therapy at a slower rate than those taking a sulfonylurea and metformin. The study suggests that real-world data may provide insight into the effects of different oral treatment regimens on the initiation of insulin use.

A new strategy for diabetes treatment

Scientists at Harvard University have identified a newly discovered compound that can slow the degradation of insulin in animals, potentially leading to a new treatment for diabetes. The compound inhibits insulin-degrading enzyme (IDE), elevating insulin levels and promoting insulin signaling in mice.

SourceHarvard University·JournalNature·DateMay 21, 2014

The Lancet Diabetes & Endocrinology: Intensive insulin provides survival

A landmark study shows that intensive insulin treatment significantly improves survival in patients with type 2 diabetes who have had a heart attack. The trial, which followed patients for up to 20 years, found that those who received intensified insulin treatment survived an average of 2.3 years longer than those on standard treatment.

SourceThe Lancet·JournalThe Lancet Diabetes & Endocrinology·DateMay 12, 2014

Cause for exaggerated insulin response in subset of bariatric surgery patients identified

Researchers at the University of Cincinnati have discovered that gastric bypass surgery leads to excessive post-meal insulin response in a subset of patients, characterized by altered islet cell function and reduced insulin clearance. This study sheds light on mechanisms of glucose metabolism alterations following gastric bypass surgery.

SourceUniversity of Cincinnati·JournalJournal of Endocrinology and Metabolism·DateMar 27, 2014

Model predicts blood glucose levels 30 minutes later

A mathematical model developed by Penn State researchers can accurately predict blood glucose levels of individuals with type 1 diabetes up to 30 minutes in advance. This allows for timely action to be taken and reduces the risk of hypoglycemic events, which can be life-threatening.

SourcePenn State·JournalJournal of Diabetes Science and Technology·DateMar 25, 2014

Type 1 diabetes in adults: Antibody affinity is decisive

Researchers at Helmholtz Munich have found that GAD antibody affinity is a key indicator of LADA disease progression. The study used GAD vaccination to examine the impact on antibody affinity in 46 LADA patients, finding no influence from vaccination. Patients with high affinity had low insulin production and required insulin therapy s...

Silencing inhibitor of cell replication spurs beta cells to reproduce

Researchers replicated human pancreatic beta cells in a mouse model using a silencing inhibitor, showcasing their ability to replicate while maintaining mature properties. The study's findings have implications for developing treatments to enhance beta-cell mass and insulin production for both type 1 and 2 diabetic patients.

SourceUniversity of Pennsylvania School of Medicine·JournalJournal of Clinical Investigation·DateJan 16, 2014

Insulin 'still produced' in most people with type 1 diabetes

New technology enabled scientists to prove that most people with type 1 diabetes have active beta cells producing insulin in response to food, contrary to previous thought. This finding has significant implications for understanding the biology of Type 1 diabetes and may lead to new therapies to preserve or replenish beta cells.

SourceDiabetologia·JournalDiabetologia·DateOct 9, 2013

A link between zinc transport and diabetes

Researchers found that SLC30A8 zinc transporter is crucial for insulin clearance by the liver and signals to stop releasing insulin. The study also discusses the dynamic regulatory role of zinc in insulin regulation.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateSep 24, 2013

New password in a heartbeat

Researchers at Rice University have developed a secure system to protect wireless implantable medical devices from unauthorized access. The technology uses the patient's unique heartbeat as a password, which can only be accessed through touch with a programmer device. This provides a secure way to monitor patients and prevent potential...